目的 觀察奧扎格雷鈉注射液聯(lián)合長(zhǎng)春西汀注射液治療椎–基底動(dòng)脈供血不足的臨床療效及安全性。方法 選擇2010年1月—2012年11月諸城市人民醫(yī)院確診的150例椎–基底動(dòng)脈供血不足的病人，隨機(jī)分為治療組（80例）和對(duì)照組（70例），對(duì)照組患者給予80 mg奧扎格林鈉＋生理鹽水250 mL，靜脈滴注，2 次/d。治療組給予30 mg長(zhǎng)春西汀＋250 mL生理鹽水，靜脈滴注，1 次/d，奧扎格林鈉的用法及用量同對(duì)照組。兩組均連續(xù)治療14 d。治療結(jié)束后，觀察兩組患者的治療效果、TCD血管流速改變情況以及不良反應(yīng)發(fā)生情況。結(jié)果 治療組和對(duì)照組總有效率分別為96.2%、82.8%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）；治療組TCD收縮峰流速改善高于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。不良反應(yīng)發(fā)生率差異無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05）。結(jié)論 奧扎格雷鈉聯(lián)合長(zhǎng)春西汀治療椎–基底動(dòng)脈供血不足具有較好療效，臨床應(yīng)用安全。

Objective To evaluate the clinical efficiency and security of Ozagreiner Injection combined with Vinpocetine Injection (OI-VI) on vertebro-basicarterial ischemia. Methods The patients (150 cases) diagnosed as vertebro-basicarterial ischemia in Zhucheng People’s Hospital from January 2010 to November 2012 were randomly divided into treatment group (80 cases) and control group (70 cases). Patients in the control group were iv administered with OI (80 mg) added into 250 mL physiological saline, twice daily for 14 d. Patients in the treatment group were iv administered with VI (30 mg) added into 250 mL physiological saline, once daily for 14 d, and the usage and dosage of OI were the same as the control group. After treatment, the therapeutic effects, blood flow changes from TCD and adverse reactions were observed. Results The efficiency of the treatment and control groups was 96.2% and 82.8% with the significant difference (P < 0.05). The peak systolic velocity from TCD in the treatment group was higher than that in the control group (P < 0.05), and the adverse reactions between the two groups had no significant difference (P > 0.05). Conclusion The clinical efficacy of OI-VI is better in the treatment of vertebro-basicarterial ischemia and the therapeutic effect is reliable and safe.